Rec­om­men­da­tions

10.30 Use as­pirin ther­a­py (75–162 mg/‍day) as a sec­ondary pre­ven­tion strat­e­gy in those with di­a­betes and a his­to­ry of atheroscle­rot­ic car­dio­vas­cu­lar dis­ease. A

10.31 For pa­tients with atheroscle­rot­ic car­dio­vas­cu­lar dis­ease and doc­u­ment­ed as­pirin al­ler­gy, clopi­do­grel (75 mg/‍day) should be used. B

10.32 Dual an­tiplatelet ther­a­py (with low-‍dose as­pirin and a P2Y12 in­hibitor) is rea­son­able for a year after an acute coro­nary syn­drome A and may have benefits be­yond this pe­ri­od. B

10.33 As­pirin ther­a­py (75–162 mg/‍day) may be con­sid­ered as a pri­ma­ry pre­ven­tion strat­e­gy in those with di­a­betes who are at in­creased car­dio­vas­cu­lar risk, after a dis­cussion with the pa­tient on the benefits ver­sus in­creased risk of bleed­ing. C